Introduction
Since the first use of antibody-enzyme conjugates in ELISA, there has been considerable progress in the application of protein/protein and protein/peptide conjugates in immunological studies (6).
Several investigations have indicated the potential ofsynthctic peptide conjugates as vaccines (1, 13) . Conjugates ofsynthetic peptides and carrier proteins can also be used to raise monospecific pobycbonal and monoclonal antibodies that crossreact with the native protein from which the peptide sequence was derived (3, 4, 11 peptides were added to GA-activated AP in a molar ratio of 100 molar equivalents.
The mixtures were stirred for 16 hr at 4'C. To block the remaining active GA groups, 100 tl 0.2 M lysine-HCI was added to the mixtures, followed by a 2-hr incubation period at 4'C. The excess peptide and lysine molecules were removed by dialysis against PBS. The obtamed conjugates were encoded SP082-AP (urea), SP082-AP (PBS), and SP082-AP (DMF), dependent on the solvent in which the coupling was carried out. The peptide-cnzyme conjugate formation was examined in an Inhibition ELISA. AlkalinePhosphataseActivity.
The enzyme activity ofthe non-conjugated AP and of the peptide-AP conjugates in the presence of urea was revealed on PVC microtiter plates (Titentek). An to Inhibit the interaction between the SP082 antisera and a coating of BSA-EDC-8P082.
The BSA-EDC-SP082 and SP082 were selected as positive con- 
Results

Determination ofAlkaline Phosphatase Activity
The enzyme activity ofnon-conjugated AP in the presence of urea is depicted in Figure  1A . 
Inhibition FLISA
The SP082-AP (PBS) and SP082-AP (urea) conjugates were abbe to inhibit the interaction of the anti-sp082 antisera with the coating ofBSA-EDC-SP082, as shown in Figure 2 . The interaction was completely inhibited when an amount of 32 tg peptide-AP conjugative conditions. We observed that the activity of the peptide-AP conjugate under these conditions was remarkably higher than the activity measured in PBS ( Figure  1B) . This suggested better availability of the enzyme active sites in the conjugate in the presence of urea.
Second, the immunological properties of the conjugated protein or peptide must not be altered by the conjugation method.
In other words, anti-pcptide antibodies must recognize the conjugated peptide in the same way as the non-conjugated peptide.
In the inhibition ELISA, 5P082-AP (urea) and SP082-AP (DMF) conjugates inhibited the interaction between anti-SP082 antibodics and a coating ofBSA-EDC-SP082 in a way comparable to inhibition of the same reaction by non-conjugated SP082 ( Figure  2 ). coating of the microtiter plate, the AP from the SP082-AP conjugates may also contribute to the observed signal.
The AP-peptide conjugate bound in this way would increase the apparent level of the signal in the assay. Although such interference may be rebatively small, it will only contribute in a positive way to the inhibition level. Therefore, the conjugates might even be better than concluded.
The use ofa pcroxidasc-babcbed goat anti-mouse conjugate in the inhibition assay instead of an AP-labeled conjugate would rule out this presumed interference.
The presumed low peptide: AP ratio on partial denaturation of the SP082-AP (DMF) conjugate was confirmed by staining of spleen tissue sections of BSA-EDC-SP082-immunizcd mice. The lowest number of specific AFC per mm2 was detected by staining with SP082-AP (DMF) conjugate, independent of the conjugate concentration (Figure 4 ). Furthermore, there was a remarkable qualitative difference among the conjugates. The cells stained by SP082-AP (DMF)
were not of the same intensity as the cells stained by SP082-AP (urea) and SP082-AP (PBS), respectively ( Figure  3A vs Figures  3B and 3C) ) Immunol Methods 130:195, 1990 
